We use cookies for certain features and to improve your experience. See our Cookie Policy and Privacy Policy to learn more

Leafly

Shop legal, local weed.

Open
advertise on Leafly
ShopDeliveryDispensariesDealsStrainsBrandsProductsCBDDoctorsCannabis 101Social impact
  • Sign in
  • Create account
  • Strains
  • Shop
  • Shop
  • Delivery
  • Deals
  • Dispensaries
  • CBD Stores
  • Brands
  • Products
  • Learn
  • Cannabis 101
  • News
  • Leafly Learn
  • Science of cannabis
  • Doctors
  • Social impact
  • Lab partners
  • Download the Leafly App
  • Advertise on Leafly
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
    • Leafly.deGerman flag
  • Help
  • News
  • Cannabis 101
  • Growing
  • Strains & products
  • CBD
  • Politics
  • Health
  • Lifestyle
  • Science & tech
  • Industry
  • Reports
  • Canada
  • Podcasts
  • Leafly Lists
IndustryPolitics

Proposed Tax Amendments Would Benefit Cannabis Industry

Ben AdlinPublished on November 30, 2017 · Last updated July 28, 2020
Sen. Cory Gardner, R-Colo., speaks during a Senate Judiciary Committee hearing for Colorado Supreme Court Justice Allison Eid, on her nomination to the U.S. Court of Appeals for the 10th Circuit, on Capitol Hill, Wednesday, Sept. 20, 2017 in Washington. (AP Photo/Alex Brandon)

Cannabis industry leaders say it’s imperative that supporters immediately contact their US senators to push for a pair of cannabis-friendly amendments to the Republican tax bill currently being debated in the nation’s capital.

The measures, sponsored by US Sen. Cory Gardner (R-Colorado), would ease tax restrictions that currently prevent state-legal cannabis businesses from making standard business deductions on their taxes. The restriction, under an IRS provision known as 280E, forces the cannabis industry to pay a far higher tax rate than other legal businesses.

One of the two amendments, SA 1609, would remove the 280E restriction entirely for cannabis businesses that comply with state laws. A similar amendment, SA 1639, includes the additional requirement that businesses be “properly regulated”—a definition that mandates licensing provisions, track-and-trace systems, limits on advertising, and other specifications.

“Cannabis businesses often pay an effective tax rate upwards of 65-75%, compared with a normal rate of around 15-30%.”

A vote on one or both of the two proposals could come as soon as Thursday evening.

The National Cannabis Industry Association, which represents the legal cannabis industry, calls 280E “an unjust burden on state-legal cannabis businesses.” It prevents taking tax deductions on business expenses, such as payroll or rent, “on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances.”

As journalist and legalization advocate Tom Angell notes on his site Marijuana Moment, the provision was adopted in the 1980s as a way to fight organized crime:

The statute was originally intended to to stop drug cartel leaders from writing off yachts and expensive cars, but today its language means that that growers, processors and sellers of marijuana — which is still a Schedule I substance under federal law — can’t take business expense deductions that are available to operators in other sectors.

As a result, cannabis businesses often pay an effective tax rate upwards of 65-75 percent, compared with a normal rate of around 15-30 percent.

The full texts of Senate amendments 1609 and 1639 are available online. Contact information for US senators can be found on the Senate website, or you can call the US Capitol Switchboard at 202-224-3121 and request to be connected to a specific Senate office.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • Loading...
    Loading...Loading...
    Loading...
    Loading...Loading...
    Loading...Loading...
  • See all dispensaries
See all dispensaries
ColoradoCongresslegislationpolicytaxes
Ben Adlin
Ben Adlin
Ben Adlin is a Seattle-based writer and editor who specializes in cannabis politics and law. He was a news editor for Leafly from 2015-2019. Follow him on Twitter: @badlin
View Ben Adlin's articles

The latest in Industry

  • Delivered Inc.: A dispensary at your doorstep image
    Delivered Inc.: A dispensary at your doorstep
    Leafly Staff
  • Green Flash: Delivering Boston’s cannabis future image
    Green Flash: Delivering Boston’s cannabis future
    Leafly Staff
  • Celebrate 420 weekend with cannabis, community, and creativity at MARY FEST NYC image
    Celebrate 420 weekend with cannabis, community, and creativity at MARY FEST NYC
    Leafly Staff
  • America’s top cannabis events of 4/20 2025 image
    America’s top cannabis events of 4/20 2025
    Amelia Williams
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App StoreDownload Leafly Marijuana Reviews on Google Play

Business Solutions
  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Business log in

About Leafly
  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

Dispensaries in
  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

Privacy & Terms
  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2025 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.